background objective recurrence rate skull base high nasopharyngeal carcinoma npc patients cavernous sinus sphenoid sinus involvement study conducted explore impact dose boost skull base recurrence skull base survival npc patients cavernous sinus sphenoid sinus involvement methods total NUMBER stage t4 npc patients cavernous sinus sphenoid sinus involvement proved histopathology computed tomography ct treated hospital oct NUMBER nov NUMBER irradiation dose gy nasopharynx gy neck NUMBER patients NUMBER received irradiation gy skull base radiotherapy boost group NUMBER did receive irradiation skull base control group patients NUMBER control group NUMBER boost group received chemotherapy cycles survival rates recurrence NUMBER groups calculated method test results clinical characteristics patients similar NUMBER groups NUMBER skull base control rates significantly higher boost group control group NUMBER vs NUMBER NUMBER vs NUMBER NUMBER vs NUMBER respectively p0045 NUMBER survival rates slightly higher boost group control group NUMBER vs NUMBER NUMBER vs NUMBER NUMBER vs NUMBER respectively p0084 median survival time longer boost group control group NUMBER months vs NUMBER months prevalences brain damage NUMBER boost group NUMBER control group significant difference p0514 conclusion dose boost skull base reduce recurrence stage t4 npc skull base tends enhance diseasefreely survival rate npc patients cavernous sinus sphenoid sinus involvementu recommended patients NUMBER NUMBER NUMBER NUMBER fifty cisplatin based NUMBER NUMBER kaplan meier log rank NUMBER NUMBER year NUMBER NUMBER year disease freely irradiation induced disease freely NUMBER NUMBER